Stefan Ståhl received his PhD 1992, and became professor 1999. Between 2006 and 2013 he was the Dean for the School of Biotechnology, KTH. Professor Ståhl has filed a number of patents, and is the cofounded of several biotech companies, in addition he has published more than 185 scientific papers in international peer-reviewed journals (h-index 52, >9300 citations), supervised 20 PhD students to their dissertation and given over 75 lectures as invited speaker at various international meetings and conferences. His research has focused on affinity proteins, denoted affibody ligands, and to explore their potential in various therapeutic settings, including tumor targeting for medical imaging and radiotherapy applications.
Professor Ståhl is the program group leader for Next Generation Antibody Therapeutics program.